SCHEMBL26090752

SCHEMBL26090752

Brc1ccc2nn(-c3ccncc3)cc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR2 Q92731 1/20 0.47
SLC6A2 P23975 2/20 0.36
BACE1 P56817 1/20 0.36
PTGS2 P35354 2/20 0.36
HDAC8 Q9BY41 1/20 0.35
NAMPT P43490 1/20 0.35
NPM1 P06748 1/20 0.35
ALK Q9UM73 1/20 0.35
SMN1; SMN2 Q16637 4/20 0.34
KMT2A Q03164 3/20 0.34
ALDH1A1 P00352 2/20 0.34
NPC1 O15118 4/20 0.33
MAPT P10636 4/20 0.33
RAB9A P51151 4/20 0.33
MEN1 O00255 2/20 0.33
LMNA P02545 2/20 0.33
HTT P42858 2/20 0.33
MAOA P21397 1/20 0.33
CYP1A2 P05177 1/20 0.33
CYP2C19 P33261 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL28748630 0.85 ESR2 (0.66) ESR2HDAC8SMN1; SMN2KMT2AALDH1A1
SCHEMBL26683963 0.82 ESR2 (0.43) ESR2BACE1PTGS2HDAC8NPM1
SCHEMBL4150092 0.82 ESR2 (0.46) ESR2BACE1PTGS2HDAC8SMN1; SMN2
SCHEMBL31457232 0.81 ESR2 (0.47) ESR2HDAC8NPM1ALKSMN1; SMN2
SCHEMBL17731486 0.81 ESR2 (0.47) ESR2HDAC8NPM1ALKSMN1; SMN2
SCHEMBL26442788 0.80 ESR2 (0.47) ESR2BACE1PTGS2NAMPTSMN1; SMN2
SCHEMBL31457236 0.77 ESR2 (0.39) ESR2BACE1HDAC8NPM1ALK
SCHEMBL26684058 0.77 ESR2 (0.39) ESR2BACE1HDAC8NPM1ALK
SCHEMBL31467203 0.76 ESR2 (0.39) ESR2NAMPT
SCHEMBL29941110 0.75 ESR2 (0.49) ESR2SLC6A2NAMPTSMN1; SMN2KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250032454-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2025-01-30 US disclosed
EP-4419504-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE Imago Biosciences Inc. (US) 2024-08-28 EP disclosed
WO-2023069884-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2023-04-27 WO disclosed
WO-2023069884-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE IMAGO BIOSCIENCES, INC. (US) 2023-04-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250032454-A1 KDM1A INHIBITORS FOR THE TREATMENT OF DISEASE KDM1B, KDM1A, KDM2A ESR2 735/4885SLC6A2 4581/4885BACE1 4458/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.